HCW Biologics Inc
For the period ended Sep 30, 2024. Filed Nov 14, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2024 · Filed Nov 14, 2024
HCWB$0.95-6.5%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Statements of cash flows
Condensed Statements of Cash Flows
| Nine Months Ended September 30, | ||
|---|---|---|
| 2023 | 2024 | |
| Cash flows from operating activities: | ||
| Net loss | $(14,313,746) | $(26,650,541) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Depreciation and amortization | 860,634 | 501,882 |
| Stock-based compensation | 742,477 | 716,940 |
| Unrealized loss (gain) on investments, net | (248,445) | — |
| Realized loss (gain) on investments, net | (15,625) | — |
| Changes in the carrying amount of right-of-use asset | (1,045) | (418) |
| Changes in operating assets and liabilities: | ||
| Accounts receivable | (292,383) | 883,917 |
| Deposit for interest reserve | (5,250,000) | — |
| Prepaid expenses and other assets | (251,008) | 829,043 |
| Accounts payable and other liabilities | 392,802 | 12,383,171 |
| Operating lease liability | (242,990) | (56,541) |
| Net cash used in operating activities | (18,619,329) | (11,392,547) |
| Cash flows from investing activities: | ||
| Purchases of property and equipment | (2,486,950) | (148,205) |
| Proceeds for sale or maturities of short-term investments | 10,000,000 | — |
| Net cash provided by (used in) investing activities | 7,513,050 | (148,205) |
| Cash flows from financing activities: | ||
| Proceeds from issuance of common stock | 9,697 | 2,502,260 |
| Proceeds from issuance of debt | — | 6,530,000 |
| Offering costs | — | — |
| Debt repayment | (8,981) | (88,388) |
| Net cash provided by financing activities | 716 | 8,943,872 |
| Net (decrease) increase in cash and cash equivalents | (11,105,563) | (2,596,880) |
| Cash and cash equivalents at the beginning of the period | 22,326,356 | 3,595,101 |
| Cash and cash equivalents at the end of the period | $11,220,793 | $998,221 |
| Supplemental disclosure of cash flow information: | ||
| Cash paid for interest, net of amounts capitalized | $284,465 | $340,988 |
| Noncash operating, investing and financing activities: | ||
| Capital expenditures accrued, but not yet paid | $2,095,724 | $1,910,698 |
| Purchases of property and equipment included in accounts payable and other liabilities | $— | $829,207 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.